Abstract: The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

Abstract: The present invention relates to an organic compound represented by Chemical Formula 1, a composition, an organic optoelectronic device, and a display device.

Abstract: Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor.

Abstract: The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

Abstract: Materials which react with (“scavenge”) sulfur compounds, such as hydrogen sulfide and mercaptans, are useful for limiting sulfur-induced corrosion. Surface-modified particles incorporating a hexahydrotriazine moiety are disclosed and used as sulfur scavengers. These surface-modified particles are used a filter media in fixed filter systems and as additives to fluids including sulfur compounds. The hexahydrotriazine moiety can react with sulfur compounds in such a manner as to bind sulfur atoms to the surface-modified particles, thus allowing removal of the sulfur atoms from fluids such as crude oil, natural gas, hydrocarbon combustion exhaust gases, sulfur polluted air and water. The surface-modified particles may, in general, be sized to allow separation of the particles from the process fluid by sedimentation, size-exclusion filtration or the like.

Abstract: An organic light-emitting device including an emission layer including a first electrode; a second electrode facing the first electrode; and an organic layer disposed between the first electrode and the second electrode, wherein the organic layer comprises an emission layer, the emission layer comprises a first compound, a second compound, and a third compound, and the first compound and the second compound are different from each other, each of the first compound and the second compound emits light, the third compound does not emit light, and the first compound and the second compound satisfy Conditions and Inequalities as described herein.

Abstract: There is provided herein a compound of formula (I) wherein R1, R2, n, X, Q, L, m, R3 and p are as defined herein, which compounds are useful in the treatment of treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.

Abstract: An organic light emitting device and a display device, the organic light emitting device including a first electrode; a hole transport region on the first electrode; an emission layer on the hole transport region; an electron transport region on the emission layer; and a second electrode on the electron transport region, wherein the hole transport region includes a compound represented by the following Formula 1:

Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.

Abstract: An organic optoelectronic device and a display device including the same, the organic optoelectronic device including: an anode and a cathode facing each other; a light-emitting layer positioned between the anode and the cathode; a hole transport layer positioned between the anode and the light-emitting layer; an auxiliary hole transport layer positioned between the hole transport layer and the light-emitting layer; an electron transport layer positioned between the cathode and the light-emitting layer; and an auxiliary electron transport layer positioned between the electron transport layer and the light-emitting layer, wherein the auxiliary electron transport layer includes at least one kind of first compound represented by chemical formula 1, and the auxiliary hole transport layer includes at least one kind of second compound represented by a combination of a moiety represented by chemical formula 2, a moiety represented by chemical formula 3 and a moiety represented by chemical formula 4.

Abstract: The present specification provides a compound having a spiro structure represented by the following Chemical Formula 1, and an organic light emitting device including the same: wherein R1 to R8, p, q, r, s, t, u, X and Y are defined therein.

Abstract: Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor. The compound represented by Formula (I): wherein the symbols are defined in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: Organic compounds containing indolocarbazoles as electron donor connected with electron acceptors such aza-triphenylene or dibenzoquinoxaline that can improve the performance of phosphorescent organic light emitting devices are disclosed.

Abstract: The present disclosure provides, among other things, compounds and crystalline forms of compounds thereof and methods of making and using such compounds and crystalline forms of compounds. Disclosed compounds and crystalline forms are useful in electronic materials, semiconductor materials, and optoelectronic materials and devices incorporating these materials and which exhibit desirable characteristics for the same.

Abstract: Provided are a novel compound and an organic electronic device using the same. The novel compound is represented by the following Formula (I): wherein X1 and X2 are each independently C(Ra), multiple (Ra)s are the same or different, and the two (Ra)s are joined together to form an aryl ring; wherein X3 and X4 are each independently C(Rb), multiple (Rb)s are the same or different, and the two (Rb)s are joined together to form a polycyclic aromatic ring.

Abstract: Processes and compositions for scavenging hydrogen sulfide from hydrocarbon streams are disclosed that reduce, if not substantially eliminate, the formation of crystalline or amorphous solids even under cold conditions. The compositions used in the processes comprise a hexahydrotriazine component and an amphiphilic component that form a hydrophobic micelle when the hexahydrotriazine component becomes spent.

Abstract: The present invention relates to compounds according to formula (1) and formula (2), said compounds being suitable for use in electronic devices, in particular organic electroluminescent devices.

Abstract: Materials which react with (“scavenge”) sulfur compounds, such as hydrogen sulfide and mercaptans, are useful for limiting sulfur-induced corrosion. Surface-modified particles incorporating a hexahydrotriazine moiety are disclosed and used as sulfur scavengers. These surface-modified particles are used a filter media in fixed filter systems and as additives to fluids including sulfur compounds. The hexahydrotriazine moiety can react with sulfur compounds in such a manner as to bind sulfur atoms to the surface-modified particles, thus allowing removal of the sulfur atoms from fluids such as crude oil, natural gas, hydrocarbon combustion exhaust gases, sulfur polluted air and water. The surface-modified particles may, in general, be sized to allow separation of the particles from the process fluid by sedimentation, size-exclusion filtration or the like.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.

Abstract: Disclosed herein is a novel method for preparing cyclophanes, comprising forming a disulfide cyclophane by contacting a linker moiety which includes two or more thiol groups, with a metal salt and an oxidant. The disulfide cyclophane is then desulfurized to form a thiacyclophane comprising thioether bridges. This thiacyclophane optionally may be further desulfurized to form an unsaturated hydrocarbon cyclophane, which can then be reduced to form a saturated hydrocarbon cyclophane. The various cyclophanes can be synthesized in a ring form, such as a dimer, trimer or tetramer etc., or they can be synthesized in a tetrahedral or larger structure. Also disclosed are novel cyclophanes formed by the disclosed method.

Abstract: The present disclosure relates to a therapeutic agent of the formula: Z—C(?O)—(CH2)n-?-S—S—(CRR?)m-(CH2)p-C(?O)—NH—(CH2)q-NH—Y[NH—(CH2)r-X-T-W][NH—(CH2—CH—O)t(CH2)s-NH—V]??Formula I or a pharmaceutically acceptable salt thereof, useful for treating tumors, including cancers. Where the compound of Formula I also contains a radionuclide or an imaging agent or both, the compound of formula I is a theranostic agent useful for treating and diagnosing tumors, including cancers.

Abstract: The present invention provides a series of spirally configured cis-stilbene/fluorene hybrid compounds and an optoelectronic device comprising the same. The compound comprises a seven-membered ring portion. The seven-membered ring portion is composed of a cis-stilbene fragment, and a tetrahedral coordination bridging atom fragment, wherein the cis-stilbene fragment has at least one substituent, the substituent is independently a substituted or unsubstituted triazine group, pyrimidine group or phenyl group. The compounds have glass transition temperatures ranged from 156° C. to 202° C., decomposition temperatures ranged from 419° C. to 509° C., reversible electron transport property, and balanced charges motilities. In addition, a variety of experimental data have proved that these spirally configured cis-stilbene/fluorene hybrid materials can indeed be used as a hole-blocking type electron-transporter for phosphorescent OLEDs.

Abstract: The invention relates to an improved process for the manufacture of bis-resorcinyl triazines of formula (I) wherein R1 is a C1C18alkyl group or C2-C18alkenyl group as well as the respective alkyl substituted bis-resorcinyl derivatives of formula (II) wherein R1 is a C1-C18alkyl group or C2-C18alkenyl group and R2 and R3 are independently of each other a C1-C18alkyl group or a C2-C18alkenyl group.

Abstract: The invention relates to an improved process for the manufacture of bis-resorcinyl triazines of formula (I), wherein R1 is hydrogen, a C1-C18 alkyl group or a C2-C18 alkenyl group and R2 is a C1-C18 alkyl group or a C2-C18 alkenyl group.

Abstract: An azine compound represented by the formula (1), a method for its production and an organic electroluminescent device containing it as a constituent component. wherein Ad each independently represents a 1-adamantyl group, etc., p and q are each independently 0 or 1, Ar1 and Ar2 are each independently a single bond (but only when p is 1, or q is 1), or a pyridyl group which may be substituted by a phenyl group, etc., incidentally, Ad groups on Ar1 and Ar2 are each independently bonded to said pyridyl group, etc., Ar2 is each independently a C3-13 heteroaromatic group which may be substituted by a fluorine atom, etc., X1, X2, X3 and X4 are each independently a single bond, etc., m and n are each independently 0, 1 or 2, Z is a nitrogen atom, etc., n+p+q is 1, 2 or 3.

Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.

Abstract: A novel organometallic complex which can emit phosphorescence is provided. A light-emitting element, a light-emitting device, an electronic device, or a lighting device with high emission efficiency is provided. The organometallic complex having an aryl triazine derivative as a ligand is represented by General Formula (G1) below as a representative of the organometallic complex of the present invention.

Abstract: A nitrogen-containing heteroaromatic compound is represented by the following formula (A). wherein Y is an oxygen atom or a sulfur atom, M is a substituted or unsubstituted nitrogen-containing heteroaromatic group, and Ar2 is a substituted aromatic hydrocarbon group having 6 to 18 ring carbon atoms, a substituted or unsubstituted monocyclic heteroaromatic group having 5 or 6 ring atoms, a dibenzofuran ring group that may be substituted with a substituent (excluding a 3-carbazolyl group and an N-carbazolyl group), a dibenzothiophene ring group that may be substituted with a substituent (excluding a 3-carbazolyl group and an N-carbazolyl group), or a nitrogen-containing polycyclic group among nitrogen-containing polycyclic groups respectively represented by the following formulas (1) to (5).

Abstract: The present invention relates to a UV absorber-comprising urethane acrylate, to a process for its preparation, and to the use thereof. The UV absorber is chemically bonded into the system.

Abstract: The present invention relates to a two-stage preparation process for an organic UV absorber that has a (meth)acrylate group in the molecule and which as a result is particularly suitable for curable UV protective coatings.

Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.

Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.

Abstract: The present invention mainly provides a new imidazole compound, which can be used to produce electronic devices that are able to operate at low driving voltage and at high current efficiency. The new imidazole compound of the present invention is represented by the following formula (1): (In the formula (1), R1 and R2 are respectively the same as described in the specification).

Abstract: Process for the preparation of triazinyl-substituted oxindoles of formula (3) and salts thereof by reacting an oxindole (1) with a triazine (2) in the presence of a carbonate, a hydroxide, a phosphate or a mixture of two or more of the aforementioned compounds, and also the compounds of formula (3) and salts thereof (3?) and the use of both for producing crop protection agents.

Abstract: Process for the selective N-sulfonylation of oxindoles, in particular process for the N-sulfonylation of 3-triazinyloxindoles, and also N-sulfonyl-substituted 3-triazinyloxindoles and the use of N-sulfonyl-substituted oxindoles and of N-sulfonyl-substituted 3-triazinyloxindoles as intermediates for the synthesis of fine chemicals and of active ingredients in the field of pharmacy and agriculture, and also the use of these compounds as active ingredients in the field of agriculture.

Abstract: The present disclosure provides a novel compound capable of greatly improving the lifetime, efficiency, electrochemical stability and thermal stability of an organic electronic device, and an organic electronic device including an organic compound layer containing the compound.

Abstract: The invention is directed to bipyridine-based compound and organic light emitting diodes (OLED) including organic layers having the bipyridine-based compound. OLEDs including organic layers having the bipyridine-based compounds can have low driving voltages, high current densities, high efficiencies and long lifetimes.

Abstract: Compounds according to Formula 1, devices containing the same and formulations containing the same are described. Formula 1 has the following structure: where at least two of R1—R10 are not H, where at least one of R1—R10 has the formula T1 where L is an organic linker, where Y1 to Y4 are CR or N, where adjacent R moieties can form fused rings, where Rs and Rt are independently aryl or heteroaryl, either of which may independently be further substituted, and where Rs and Rt do not form fused rings with any part of the molecule.

Abstract: A hole transport material for an organic electroluminescence (EL) device, and an EL device including the same, the hole transport material being represented by Formula 1, below:

Abstract: The present disclosure provides a nitrogen-containing heterocyclic compound and an organic electronic device comprising the same. The organic electronic device according to the present disclosure shows excellent characteristics in terms of efficiency, driving voltage and lifespan.

Abstract: A cyclic azine compound represented by general formula (1): wherein each Ar1 represents an aromatic group, which is unsubstituted or substituted by a C1-4 alkyl group, a phenyl group or a pyridyl group; and A represents a group selected from those which are represented by general formulae (2) to (5), described in the description. The cyclic azine compound is useful for an organic compound layer of fluorescent or phosphorescent EL device.

Abstract: Compounds (including polymers) for use in hybrid host materials which can be used in electroluminescent devices. The compounds comprise at least one electron-transporting moiety and at least one hole-transporting moiety which are joined by a flexible linker. Hybrid host materials comprising the compounds exhibit stability against phase separation, elevated glass transition temperature, morphological stability against crystallization, and isolation of the electron transporting moiety and hole transporting moiety ?-systems.

Abstract: The present invention relates to a novel organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound according to the present invention has excellent luminous efficiency, power efficiency, and lifespan characteristic. Using the compounds of the present invention, it is possible to manufacture an OLED device with a long operating lifespan. In addition, the compounds can improve the power efficiency of the device to reduce overall power consumption.

Abstract: The present application relates to novel substituted fused imidazoles and pyrazoles, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases and to the use thereof producing medicaments for the treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

Abstract: A chrysene-based compound and an organic light-emitting device including the same, the chrysene-based compound being represented by Formula 1, below:

Abstract: Disclosed herein are compounds of formula I: X-(L-Z)p-L-R[L-(Z-L)p-Y]q??(I) wherein L is a perfluoropolyether; R is q can be an integer equal to or greater than 1; p can independently be integers from 0 to 7; X and Y can independently be chosen from: —OH, —CH2CH2OH, CH2CH2OCH2CH2OH, —CH2CH(OH)CH2OH, —C6H5, —CH2C6H5, —CH2CH(OH)CH3, F, —CF3, —CF2CF3, piperonyl, triazine, benzotriazole, and derivatives thereof; and Z, if present, can independently be chosen from: —C6H4—, —CH2C6H4CH2—, —CH2CH(OH)CH2—, —CH2CH(OH)CH2CH(OH)CH2—, —CH(OH)CH(OH)CH2—, —CH(CH2OH)—, or —CH(C6H5)—.

Abstract: Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.

Abstract: A compound for an organic photoelectric device and an organic photoelectric device including the same, the compound being represented by the following Chemical Formula 1:

Abstract: A compound having a benzotriazole ring structure and a formula (1): wherein Ar is a substituted or unsubstituted aromatic hydrocarbon group, aromatic heterocyclic group, or condensed polycyclic aromatic group; A and B are the same as or different from each other and each represent a hydrogen atom or a monovalent group of formula (2), provided that A and B are not simultaneously hydrogen atoms: wherein R1 to R8 are the same as or different and each represent a hydrogen atom, a deuterium atom, a fluorine atom, a chlorine atom, a cyano group, a trifluoromethyl group, a linear or branched alkyl group having 1 to 6 carbon atoms, aromatic hydrocarbon group, a substituted or unsubstituted aromatic heterocyclic group, or condensed polycyclic aromatic group; m is an integer of 0, 1 or 2; X represents a carbon atom or a nitrogen atom; when X is a nitrogen atom, the nitrogen atom does not have substituents or bonding groups of R1, R2, R3 and R4; and when m is 2, a plurality of R1, R2, R3, R4 and X each are the